WallStSmart

Equinor ASA ADR (EQNR)vsIntuitive Surgical Inc (ISRG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Equinor ASA ADR generates 953% more annual revenue ($105.98B vs $10.06B). ISRG leads profitability with a 28.4% profit margin vs 4.8%. ISRG appears more attractively valued with a PEG of 2.43. ISRG earns a higher WallStSmart Score of 62/100 (C+).

EQNR

Hold

45

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 2.32

ISRG

Buy

62

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 4.7Quality: 7.8
Piotroski: 4/9Altman Z: 6.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EQNRSignificantly Overvalued (-116.7%)

Margin of Safety

-116.7%

Fair Value

$13.19

Current Price

$40.46

$27.27 premium

UndervaluedFair: $13.19Overvalued
ISRGSignificantly Overvalued (-78.8%)

Margin of Safety

-78.8%

Fair Value

$262.88

Current Price

$469.98

$207.10 premium

UndervaluedFair: $262.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EQNR3 strengths · Avg: 8.3/10
Market CapQuality
$103.74B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

ISRG5 strengths · Avg: 9.2/10
Operating MarginProfitability
30.2%10/10

Strong operational efficiency at 30.2%

Altman Z-ScoreHealth
6.1810/10

Safe zone — low bankruptcy risk

Market CapQuality
$167.61B9/10

Large-cap with strong market position

Profit MarginProfitability
28.4%9/10

Keeps 28 of every $100 in revenue as profit

Revenue GrowthGrowth
18.8%8/10

18.8% revenue growth

Areas to Watch

EQNR4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.572/10

Expensive relative to growth rate

Revenue GrowthGrowth
-5.1%2/10

Revenue declined 5.1%

ISRG3 concerns · Avg: 3.3/10
PEG RatioValuation
2.434/10

Expensive relative to growth rate

Price/BookValuation
9.4x4/10

Trading at 9.4x book value

P/E RatioValuation
59.9x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : EQNR

The strongest argument for EQNR centers on Market Cap, Price/Book, Operating Margin.

Bull Case : ISRG

The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 28.4% and operating margin at 30.2%. Revenue growth of 18.8% demonstrates continued momentum.

Bear Case : EQNR

The primary concerns for EQNR are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 4.8% margins leave little buffer for downturns.

Bear Case : ISRG

The primary concerns for ISRG are PEG Ratio, Price/Book, P/E Ratio. A P/E of 59.9x leaves little room for execution misses.

Key Dynamics to Monitor

EQNR profiles as a value stock while ISRG is a growth play — different risk/reward profiles.

ISRG carries more volatility with a beta of 1.68 — expect wider price swings.

ISRG is growing revenue faster at 18.8% — sustainability is the question.

ISRG generates stronger free cash flow (730M), providing more financial flexibility.

Bottom Line

ISRG scores higher overall (62/100 vs 45/100), backed by strong 28.4% margins and 18.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Equinor ASA ADR

ENERGY · OIL & GAS INTEGRATED · USA

Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.

Intuitive Surgical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.

Want to dig deeper into these stocks?